GlassScriptPhysician profile
James M Polo
NPI 1093731168
$21,066.13
in general payments reported to CMS, 2019-2025
32 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,461 · 2021: $1,496 · 2022: $2,027 · 2023: $2,144 · 2024: $1,934 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,603 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,602.86 |
| Education | $192.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,328.76 | 2019-2025 | |
| Abbvie INC. | $2,729.22 | 2019-2025 | |
| Genzyme Corporation | $1,251.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,079.48 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,058.35 | 2020-2025 | Ilumya, Blu-U, Winlevi |
| Janssen Biotech, INC. | $880.55 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $835.47 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $597.89 | 2020-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $323.46 | 2019-2025 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $306.52 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $262.05 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Amgen INC. | $253.15 | 2019-2024 | Otezla |
| Biofrontera INC. | $163.44 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $155.74 | 2021-2024 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.42 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $99.22 | 2019-2022 | |
| Celgene Corporation | $85.81 | 2019 | |
| Lilly USA, LLC | $79.91 | 2019-2023 | Olumiant, Taltz |
| Organon LLC | $77.72 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $67.70 | 2019-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $44.01 | 2019-2020 | |
| Incyte Corporation | $36.82 | 2022 | |
| Dusa Pharmaceuticals, INC. | $33.01 | 2019 | |
| Vyne Pharmaceuticals INC. | $30.12 | 2020 | |
| Strata Skin Sciences, INC. | $27.13 | 2021 | |
| Convatec INC. | $25.65 | 2024 | |
| Kyowa Kirin, INC. | $20.47 | 2022 | |
| Aclaris Therapeutics, INC. | $19.95 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.38 | 2023 | |
| Mimedx Group, INC. | $15.92 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.72 | 2025 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Polo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.